Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Finished Goods (2023 - 2025)

Historic Finished Goods for Tarsus Pharmaceuticals (TARS) over the last 3 years, with Q3 2025 value amounting to $2.8 million.

  • Tarsus Pharmaceuticals' Finished Goods rose 12607.66% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 12607.66%. This contributed to the annual value of $2.0 million for FY2024, which is 100219.78% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Finished Goods stood at $2.8 million, which was up 12607.66% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Finished Goods ranged from a high of $2.8 million in Q3 2025 and a low of $182000.0 during Q4 2023
  • For the 3-year period, Tarsus Pharmaceuticals' Finished Goods averaged around $1.5 million, with its median value being $1.6 million (2024).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Finished Goods soared by 100219.78% in 2024, and later surged by 12607.66% in 2025.
  • Tarsus Pharmaceuticals' Finished Goods (Quarter) stood at $182000.0 in 2023, then surged by 1002.2% to $2.0 million in 2024, then surged by 41.33% to $2.8 million in 2025.
  • Its Finished Goods stands at $2.8 million for Q3 2025, versus $2.3 million for Q2 2025 and $1.9 million for Q1 2025.